MiMedx Group Inc
NASDAQ:MDXG

Watchlist Manager
MiMedx Group Inc Logo
MiMedx Group Inc
NASDAQ:MDXG
Watchlist
Price: 5.94 USD 2.24% Market Closed
Market Cap: 877.3m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one MDXG stock under the Base Case scenario is 7.01 USD. Compared to the current market price of 5.94 USD, MiMedx Group Inc is Undervalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MDXG Relative Value
Base Case
7.01 USD
Undervaluation 15%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.5
P/S
P/S
Price to Sales
2.5
vs History
61
vs Industry
69
Median 3Y
2.7
Median 5Y
2.8
Industry
7
Forward
2.3
More Details
21.8
P/E
P/E
Price to Earnings
21.8
vs History
14
vs Industry
6
Median 3Y
-8.6
Median 5Y
-13
Industry
22.7
Forward
23.5
More Details
13.4
P/OCF
P/OCF
Price to OCF
13.4
vs History
33
vs Industry
10
Median 3Y
14.5
Median 5Y
-21.1
Industry
19.4
More Details
14.1
P/FCFE
P/FCFE
Price to FCFE
14.1
vs History
28
vs Industry
5
Median 3Y
-15.3
Median 5Y
-20
Industry
22.6
More Details
4.3
P/B
P/B
Price to Book Value
4.3
vs History
96
vs Industry
16
Median 3Y
6
Median 5Y
7.1
Industry
2.6
More Details
2.2
EV/S
EV/S
Enterprise Value to Sales
2.2
vs History
65
vs Industry
61
Median 3Y
2.5
Median 5Y
2.6
Industry
7.3
Forward
2.1
More Details
2.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.7
vs History
65
vs Industry
61
Median 3Y
3.1
Median 5Y
3.1
Industry
9.4
More Details
15.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.7
vs History
58
vs Industry
7
Median 3Y
15.6
Median 5Y
18.2
Industry
4.6
Forward
9.9
More Details
17.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
17.4
vs History
53
vs Industry
7
Median 3Y
17.3
Median 5Y
18.9
Industry
4.5
Forward
16.6
More Details
12
EV/OCF
EV/OCF
Enterprise Value to OCF
12
vs History
33
vs Industry
11
Median 3Y
13.1
Median 5Y
-19.5
Industry
5
More Details
12.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
12.2
vs History
33
vs Industry
8
Median 3Y
13.3
Median 5Y
-18
Industry
3.7
More Details
5.1
EV/IC
EV/IC
Enterprise Value to IC
5.1
vs History
74
vs Industry
24
Median 3Y
6.2
Median 5Y
6.6
Industry
4.9
More Details

Multiples Across Competitors

MDXG Competitors Multiples
MiMedx Group Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
MiMedx Group Inc
NASDAQ:MDXG
876.8m USD 2.5 21.8 15.7 17.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 210 659 -162 598.2 -197 446.1 -195 193
US
Abbvie Inc
NYSE:ABBV
324.6B USD 5.7 78.1 14.9 22.1
US
Amgen Inc
NASDAQ:AMGN
146.5B USD 4.3 24.7 13.5 22.3
US
Gilead Sciences Inc
NASDAQ:GILD
132.2B USD 4.6 22.2 9.7 13.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114B USD 10.3 -115.3 24.5 25.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 059.3 -525.5 -572.2 -556.9
AU
CSL Ltd
ASX:CSL
116.5B AUD 5 27.5 17 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.4B USD 3.9 12.3 10.9 12.2
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.8 -65.6 -59.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.8B USD 17.4 -151.3 -678 -339.7
P/E Multiple
Earnings Growth PEG
US
MiMedx Group Inc
NASDAQ:MDXG
Average P/E: 31.1
21.8
9%
2.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 598.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.2
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -115.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.5 N/A N/A
AU
CSL Ltd
ASX:CSL
27.5
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -151.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
MiMedx Group Inc
NASDAQ:MDXG
Average EV/EBITDA: 15.2
15.7
23%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.7
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.2 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -678 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
MiMedx Group Inc
NASDAQ:MDXG
Average EV/EBIT: 19.2
17.4
13%
1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 193 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.1
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.6
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -339.7 N/A N/A

See Also

Summary
MDXG intrinsic value, competitors valuation, and company profile.
DCF Valuation
MDXG stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MDXG stock valuation using valuation multiples.
Wall Street Estimates
MDXG price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MDXG stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 263,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.